Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2002 4
2003 10
2004 12
2005 14
2006 15
2007 18
2008 15
2009 29
2010 26
2011 30
2012 39
2013 45
2014 44
2015 46
2016 50
2017 41
2018 54
2019 62
2020 84
2021 66
2022 71
2023 67
2024 61
2025 85
2026 26

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

939 results

Results by year

Filters applied: . Clear all
Page 1
Immunogenicity of Extracellular Vesicles.
Xia Y, Zhang J, Liu G, Wolfram J. Xia Y, et al. Among authors: zhang j. Adv Mater. 2024 Aug;36(33):e2403199. doi: 10.1002/adma.202403199. Epub 2024 Jun 27. Adv Mater. 2024. PMID: 38932653 Review.
Efficacy and safety of bilastine vs. levocetirizine for the treatment of chronic idiopathic urticaria: A multicenter, double-blind, double-dummy, phase III, non-inferiority, randomized clinical trial.
Chen X, Han X, Cheng B, Li H, Liu L, Geng S, Li L, Li J, Guo Q, Zhang G, Fang H, Zhang J. Chen X, et al. Among authors: zhang j. Chin Med J (Engl). 2024 Jun 20;137(12):1480-1482. doi: 10.1097/CM9.0000000000003071. Epub 2024 Apr 1. Chin Med J (Engl). 2024. PMID: 38557589 Free PMC article. Clinical Trial. No abstract available.
A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis.
Cai L, Jiang C, Zhang G, Fang H, Wang J, Li Y, Xu H, Xiao R, Ding Y, Huang K, Zhang C, Zhang L, Chen B, Duan X, Pan W, Han G, Chen R, Liu L, Zhang S, Tao J, Pang X, Yu J, Wang H, Zhao Y, Li C, Kang X, Qin L, Zhu X, Su J, Li S, Yang C, Feng W, Lei T, Jiang S, Fang R, Lin M, Lu Q, Xu C, Wang W, Zhang J. Cai L, et al. Among authors: zhang j. Br J Dermatol. 2024 Aug 14;191(3):336-343. doi: 10.1093/bjd/ljae062. Br J Dermatol. 2024. PMID: 38366639 Clinical Trial.
939 results